These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22045112)

  • 1. Use of OROS® hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting doses.
    Ringe JD; Schäfer S; Wimmer AM; Giesecke T
    Wien Klin Wochenschr; 2012 Jan; 124(1-2):25-31. PubMed ID: 22045112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
    Rauck R; Rapoport R; Thipphawong J
    Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Oral osmotic hydromorphone (OROS) in patients with chronic severe pain due to osteoarthritis under daily routine conditions].
    Müller-Schwefe GH; Blimke B; Hesselbarth S; Giesecke T
    MMW Fortschr Med; 2014 Apr; 156 Suppl 1():23-9. PubMed ID: 24930329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study.
    Song EK; Shim H; Han HS; Sun D; Lee SI; Kang MH; Lee K; Cho D; Cho IS; Park SY; Kim S; Yim CY
    Pain Res Manag; 2015; 20(6):293-9. PubMed ID: 26474382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.
    Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC
    Int J Clin Pract; 2007 Oct; 61(10):1671-6. PubMed ID: 17877652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
    Wallace M; Skowronski R; Khanna S; Tudor IC; Thipphawong J
    Curr Med Res Opin; 2007 May; 23(5):981-9. PubMed ID: 17519065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
    Nalamachu SR; Kutch M; Hale ME
    J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of OROS® hydromorphone ER in adults with chronic noncancer and cancer pain: pooled analysis of 13 studies.
    Hale ME; Wallace MS; Taylor DR; Kutch M; Nalamachu S
    J Opioid Manag; 2012; 8(5):299-314. PubMed ID: 23247907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain.
    Wallace M; Moulin DE; Rauck RL; Khanna S; Tudor IC; Skowronski R; Thipphawong J
    J Opioid Manag; 2009; 5(2):97-105. PubMed ID: 19507806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
    Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
    Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs.
    Coluzzi F; Mattia C
    Minerva Anestesiol; 2010 Dec; 76(12):1072-84. PubMed ID: 21102402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
    Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
    J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.
    Park CK; Kang HW; Oh IJ; Kim YC; Kim YK; Na KJ; Ahn SJ; Kim TO; Choi YJ; Song GA; Lee MK
    J Korean Med Sci; 2016 Dec; 31(12):1914-1921. PubMed ID: 27822929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of OROS® hydromorphone in patients suffering from severe chronic pain: A Study undertaken in routine clinical practice.
    Stepanović A; Pirc J; Lahajnar Čavlović S
    Wien Klin Wochenschr; 2011 Sep; 123(17-18):531-5. PubMed ID: 21710117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
    Nalamachu S; Ruck D; Nalamasu R; Fasbinder S; Bansal R
    J Opioid Manag; 2013; 9(1):43-9. PubMed ID: 23709303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
    Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
    Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.
    Hale ME; Nalamachu SR; Khan A; Kutch M
    J Pain Res; 2013; 6():319-29. PubMed ID: 23658495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.